With maturity comes confidence: EBCTCG tamoxifen update

被引：17
作者：
Chia, Stephen K. [1 ]
Wolff, Antonio C. [2 ]
机构：
[1] Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Johns Hopkins Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
LANCET | 2011年 / 378卷 / 9793期
关键词：
ADJUVANT ENDOCRINE THERAPY; BREAST-CANCER; WOMEN;
D O I：
10.1016/S0140-6736(11)61128-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：747 / 749
页数：3
相关论文
共 17 条
  • [1] Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
    Albain, Kathy S.
    Barlow, William E.
    Ravdin, Peter M.
    Farrar, William B.
    Burton, Gary V.
    Ketchel, Steven J.
    Cobau, Charles D.
    Levine, Ellis G.
    Ingle, James N.
    Pritchard, Kathleen I.
    Lichter, Allen S.
    Schneider, Daniel J.
    Abeloff, Martin D.
    Henderson, I. Craig
    Muss, Hyman B.
    Green, Stephanie J.
    Lew, Danika
    Livingston, Robert B.
    Martino, Silvana
    Osborne, C. Kent
    [J]. LANCET, 2009, 374 (9707) : 2055 - 2063
  • [2] Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]
  • [3] Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    Cuzick, Jack
    Sestak, Ivana
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Dowsett, Mitch
    Forbes, John F.
    [J]. LANCET ONCOLOGY, 2010, 11 (12) : 1135 - 1141
  • [4] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
    Davies, C.
    Godwin, J.
    Gray, R.
    Clarke, M.
    Darby, S.
    McGale, P.
    Wang, Y. C.
    Peto, R.
    Pan, H. C.
    Cutter, D.
    Taylor, C.
    Ingle, J.
    [J]. LANCET, 2011, 378 (9793) : 771 - 784
  • [5] Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
    Dignam, James J.
    Dukic, Vanja
    Anderson, Stewart J.
    Mamounas, Eleftherios P.
    Wickerham, D. Lawrence
    Wolmark, Norman
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (03) : 595 - 602
  • [6] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
    Dowsett, Mitch
    Cuzick, Jack
    Ingle, Jim
    Coates, Alan
    Forbes, John
    Bliss, Judith
    Buyse, Marc
    Baum, Michael
    Buzdar, Aman
    Colleoni, Marco
    Coombes, Charles
    Snowdon, Claire
    Gnant, Michael
    Jakesz, Raimund
    Kaufmann, Manfred
    Boccardo, Francesco
    Godwin, Jon
    Davies, Christina
    Peto, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 509 - 518
  • [7] Ferlan J, GLOBOCAN 2008 CANC F
  • [8] Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
    Hackshaw, Allan
    Roughton, Michael
    Forsyth, Sharon
    Monson, Kathryn
    Reczko, Krystyna
    Sainsbury, Richard
    Baum, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (13) : 1657 - 1663
  • [9] Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.5858/134.6.907, 10.1200/JCO.2009.25.6529, 10.1200/JOP.777003]
  • [10] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481
12